A 30% reduction in geometric mean uACR has been suggested as a meaningful and valid surrogate of treatments for progressive CKD.8 Although urinary glucose resulting from SGLT-2 inhibition is unlikely to interfere with Jaffe assays sufficiently to result in a ≥30% change, it could result in overestimated or misleading claims of beneficial effects on uACR. The gene discussed is SLC5A2; the disease is chronic kidney disease.